Clinical Trials
101 trialsNCT03258554 2026-06-02
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT03691714 2026-06-01
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 2 Completed
NCT04590963 2026-06-01
INTERLINK-1
AstraZeneca
Phase 3 Active not recruiting
NCT03646461 2026-05-22
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
University of California, San Diego
Phase 2 Terminated
NCT01468896 2026-04-29
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03389477 2026-04-21
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT03370276 2026-04-02
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00939627 2026-03-10
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
Phase 2 Completed
NCT02979977 2026-02-04
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Yale University
Phase 2 Completed
NCT01302834 2026-01-12
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00956007 2026-01-06
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT04428151 2025-12-04
LEAP-009
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03358472 2025-12-03
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Phase 3 Completed
NCT06046482 2025-10-22
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05061420 2025-09-22
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Sanofi
Phase 2 Terminated
NCT00665392 2025-08-01
ECHO-07
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Completed
NCT02358031 2025-07-18
MK-3475-048
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04282109 2025-06-26
NIVOTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Completed
NCT04616196 2025-06-08
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Nektar Therapeutics
Phase 1/2 Completed
NCT02573493 2024-12-27
APA
Washington University School of Medicine
Phase 2 Completed
NCT03422536 2024-09-04
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
University of Arizona
Phase 2 Completed
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT01979211 2024-02-29
Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
University of Cincinnati
Phase 2 Completed
NCT01588431 2024-02-14
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01437449 2024-01-30
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Stanford University
Phase 2 Completed
NCT02101034 2023-12-21
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
Washington University School of Medicine
Phase 1/2 Completed
NCT02741570 2023-09-21
CheckMate 651
Bristol-Myers Squibb
Phase 3 Completed
NCT02499120 2023-09-08
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Pfizer
Phase 2 Completed
NCT00089297 2023-06-29
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00096174 2023-06-29
Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01084083 2023-06-28
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03769311 2023-05-24
Cetuximab in Head and Neck Cancer Patients
University of Wisconsin, Madison
Phase 2 Completed
NCT03254927 2023-04-03
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Celldex Therapeutics
Phase 2 Terminated
NCT02105636 2022-10-05
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Bristol-Myers Squibb
Phase 3 Completed
NCT00265941 2022-06-14
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT02383966 2022-05-13
CHANGE2
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT03067610 2022-03-17
INFIELD
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01104922 2022-02-14
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
University of Pittsburgh
Phase 2 Completed
NCT01332266 2022-01-03
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Eisai Inc.
Phase 1/2 Completed
NCT02052960 2021-11-02
RESGEX
Glycotope GmbH
Phase 2 Completed
NCT02551159 2021-10-13
KESTREL
AstraZeneca
Phase 3 Completed
NCT01816984 2021-10-05
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
University of Chicago
Phase 1/2 Completed
NCT03349710 2021-08-09
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT02177838 2021-04-21
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Rutgers, The State University of New Jersey
Phase NA Terminated
NCT00904345 2021-02-24
Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01663259 2021-01-19
Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT03887442 2021-01-07
EXTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Terminated
NCT01602315 2020-12-29
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Novartis
Phase 1/2 Terminated
NCT01412229 2020-11-23
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01326923 2020-10-09
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
Louisiana State University Health Sciences Center Shreveport
Phase 2 Terminated